Scholarlink

Purpose <p>To assess the clinical benefits and complications of thoracic endovascular aneurysm repair (TEVAR) using a single-branched stent-graft in patients with thoracic aortic diseases (TADs) involving the left subclavian artery (LSA).</p> Methods <p>This retrospective study reviewed patients with TADs involving the LSA treated with TEVAR using a unibody single-branched stent-graft (Castor single-branched stent-graft, Shanghai MicroPort Endovascular (Group) MedTech Co., Ltd.) from November 2017 to May 2021. Clinical follow-ups and computed tomographic angiography (CTA) were conducted at 1&#xa0;week, 3&#xa0;months, 6&#xa0;months, and annually.</p> Results <p>A total of 114 patients underwent TEVAR with Castor stent-graft. Among 114 patients, 88 had TBAD, 14 had PAU, 6 had pseudoaneurysms, 3 had TAA, and 2 had IMH. Technical success (defined as successful deployment and patency of all stent segments) was 100%. No mortality, endoleak, stroke, or paraplegia was observed during a mean follow-up of 19.8&#xa0;months. One case of LSA occlusion (0.9%) was noted at 3-month follow-up, without neurological symptoms.</p> Conclusion <p>The Castor single-branched stent-graft is effective for treating TADs involving the LSA, with high technical success and no short- or midterm complications. Further research is needed to confirm long-term safety and efficacy.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Single-Branched Stent-Graft for Thoracic Aortic Diseases Involving Left Subclavian Artery

  • 期刊论文

  • 发表日期：

    2025年9月11日

查看全文
  • Xunqiang Liu,
  • Zheng Jia,
  • Huanjun Chen,
  • Ying Yang,
  • Cuihong Li,
  • Min Ji,
  • Chunxin Yang,
  • Jinhui Zhang,
  • Lei Cong,
  • Jiaqi Li,
  • Yan Wei,
  • Liqiong Zhang,
  • Enshuai Zhu,
  • Ruhong Li

摘要

Purpose

To assess the clinical benefits and complications of thoracic endovascular aneurysm repair (TEVAR) using a single-branched stent-graft in patients with thoracic aortic diseases (TADs) involving the left subclavian artery (LSA).

Methods

This retrospective study reviewed patients with TADs involving the LSA treated with TEVAR using a unibody single-branched stent-graft (Castor single-branched stent-graft, Shanghai MicroPort Endovascular (Group) MedTech Co., Ltd.) from November 2017 to May 2021. Clinical follow-ups and computed tomographic angiography (CTA) were conducted at 1 week, 3 months, 6 months, and annually.

Results

A total of 114 patients underwent TEVAR with Castor stent-graft. Among 114 patients, 88 had TBAD, 14 had PAU, 6 had pseudoaneurysms, 3 had TAA, and 2 had IMH. Technical success (defined as successful deployment and patency of all stent segments) was 100%. No mortality, endoleak, stroke, or paraplegia was observed during a mean follow-up of 19.8 months. One case of LSA occlusion (0.9%) was noted at 3-month follow-up, without neurological symptoms.

Conclusion

The Castor single-branched stent-graft is effective for treating TADs involving the LSA, with high technical success and no short- or midterm complications. Further research is needed to confirm long-term safety and efficacy.

Graphical Abstract